PURETECH HEALTH PLC - ADR (PRTC) Stock News

USA - NASDAQ:PRTC - US7462371060 - ADR

17.5 USD

+0.26 (+1.51%)

Last: 11/7/2025, 8:09:37 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PRTC Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: PureTech Health plc

PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

18 days ago - By: PureTech Health plc

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

2 months ago - By: The Motley Fool

PureTech Health Cash Runway Extended

a month ago - By: PureTech Health plc

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

2 months ago - By: Benzinga - Mentions: WYFI SERV B FDX ...

CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday

2 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers

6 months ago - By: Benzinga - Mentions: AVB CMPR PPL LANC ...

Earnings Scheduled For April 30, 2025

2 months ago - By: The Motley Fool

PureTech (PRTC) Q2 2025 Earnings Call Transcript

2 months ago - By: PureTech Health plc

PureTech Health plc – Half-Year Report

3 months ago - By: PureTech Health plc

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

3 months ago - By: PureTech Health plc

PureTech Health: Notice of Half-Yearly Results

3 months ago - By: PureTech Health plc

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

3 months ago - By: PureTech Health plc

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

4 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

4 months ago - By: PureTech Health plc

PureTech Announces Leadership Transition

4 months ago - By: PureTech Health plc

PureTech Announces Board Change

5 months ago - By: PureTech Health plc

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement

5 months ago - By: PureTech Health plc

PureTech Health: Results of Annual General Meeting

6 months ago - By: PureTech Health plc

PureTech to Present at the Jefferies Global Healthcare Conference

6 months ago - By: PureTech

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

6 months ago - By: PureTech Health plc

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

6 months ago - By: PureTech Health plc

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

6 months ago - By: PureTech Health plc

PureTech Announces Annual Results for Year Ended December 31, 2024

7 months ago - By: PureTech Health plc

PureTech Health: Notice of Results

7 months ago - By: PureTech Health plc

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

7 months ago - By: PureTech Health plc

PureTech Health plc Statement Regarding Press Speculation

8 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

9 months ago - By: PureTech Health plc

PureTech to Present at the Leerink Partners Global Healthcare Conference

9 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

10 months ago - By: PureTech Health plc

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

10 months ago - By: PureTech Health plc

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

10 months ago - By: PureTech Health plc

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference